Cure8 news brief
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
The report also presents the first recent dedicated Phase 3 randomized data showing higher fistula remission rates with Tremfya versus placebo, which is relevant for people with perianal disease.
Adults with Crohn’s disease, especially those with perianal fistulas, patients considering or currently on biologic therapies, gastroenterologists, and IBD researchers.
The report is a news summary of company-presented Phase 3 trial results rather than a full peer-reviewed publication.
The three-year figures come from long-term extension data and show proportions of patients in remission and still on treatment; the piece does not present patient-level data, statistical testing details, or head-to-head comparisons with other therapies.
If you’re following biologic options, these findings add longer-term evidence for IL-23 inhibition (guselkumab) in Crohn’s disease and offer the first recent randomized Phase 3 data focused on perianal fistulas.
Discuss with your GI how these results might relate to your situation—especially if you have prior biologic exposure or perianal disease—since individual treatment choice depends on factors not reported in the article (prior responses, safety history, and comparative effectiveness).
The article quotes investigators and company statements and reports subgroup analyses; subgroup results can be informative but are limited without full statistical context.
This is a news report summarizing company-presented Phase 3 results at a medical meeting. The article does not replace reviewing full trial publications or regulatory updates; subgroup findings should be interpreted cautiously and the three-year extension data are not a head-to-head comparison versus other treatments.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
